Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up |
| |
| Authors: | F. W. Willem Den Otter Graham Hill Wim R. Klein Jan Willem Koten Peter A. Steerenberg Pieter H. M. De Mulder Christopher Rhode Rachel Stewart Joop A. J. Faber E. Joost Ruitenberg Victor P. M. G. Rutten |
| |
| Affiliation: | (1) Department of Functional Morphology, Faculty of Veterinary Medicine, PO Box 80.157, 3508 TD Utrecht, The Netherlands;(2) Faculty of Veterinary Science, University of Zimbabwe, P. O. Box MP 167, Harare, Zimbabwe;(3) Department of General Surgery and Large Animal Surgery, Faculty of Veterinary Medicine, Yalelaan 12, Utrecht, The Netherlands;(4) Department of Immunology, Faculty of Veterinary Medicine, Institute of Infectious Diseases and Immunology, Yalelaan 1, Utrecht, The Netherlands;(5) Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Plesmanlaan 125, Amsterdam, The Netherlands;(6) Laboratory of Pathology, National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands;(7) Department of Medicine, Division of Medical Oncology, University of Nijmegen, The Netherlands;(8) Center for Biostatistics, Padualaan 4, Utrecht, The Netherlands |
| |
| Abstract: | We have tested the therapeutic potency of peritumorally injected low doses of interleukin-2(IL-2). Seventy tumours of the bovine ocular squamous-cell carcinoma (BOSCC), 1–3 cm in diameter, were treated with 5000, 20 000 or 200 000 U IL-2 from Eurocetus (Chiron) to find the optimal dose for treatment. Injections were given peritumorally on Monday to Friday on 2 consecutive weeks. The size of the tumours was measured before treatment and 1, 3, 4, 9 and 20 months after treatment. After 9 months complete regression was observed in 89% of the tumours treated with 5000 U IL-2, 80% treated with 20 000 U and 67% treated with 200 000 U. After 20 months, there was complete regression of 35%, 31% and 67% of the tumours respectively. The 9-and 20-month results of the 200 000-U treatment are significantly better than those of the 5000-U and 20 000-U treatments taken together. This protocol may be useful to treat advanced inoperable tumours (e.g. of the nasopharynx or skin) of human patients. |
| |
| Keywords: | IL-2 therapy Cancer Immunotherapy Bovine ocular squamous-cell carcinoma |
| 本文献已被 SpringerLink 等数据库收录！ |
|
